885 related articles for article (PubMed ID: 16580898)
1. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
[TBL] [Abstract][Full Text] [Related]
2. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
3. VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.
Oner Ozgon G; Langaee TY; Feng H; Buyru N; Ulutin T; Hatemi AC; Siva A; Saip S; Johnson JA
Eur J Clin Pharmacol; 2008 Sep; 64(9):889-94. PubMed ID: 18542936
[TBL] [Abstract][Full Text] [Related]
4. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
Miao L; Yang J; Huang C; Shen Z
Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
[TBL] [Abstract][Full Text] [Related]
5. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
[TBL] [Abstract][Full Text] [Related]
6. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
[TBL] [Abstract][Full Text] [Related]
8. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
[TBL] [Abstract][Full Text] [Related]
9. [Association between CYP2C9 and VKORC1 genetic polymorphism and warfarin dose requirements].
Yang J; Miao LY; Huang CR; Shen ZY; Jiang WP
Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Feb; 36(2):137-40. PubMed ID: 19099951
[TBL] [Abstract][Full Text] [Related]
10. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
[TBL] [Abstract][Full Text] [Related]
11. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.
Loebstein R; Vecsler M; Kurnik D; Austerweil N; Gak E; Halkin H; Almog S
Clin Pharmacol Ther; 2005 May; 77(5):365-72. PubMed ID: 15900282
[TBL] [Abstract][Full Text] [Related]
12. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
[TBL] [Abstract][Full Text] [Related]
13. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement.
Herman D; Peternel P; Stegnar M; Breskvar K; Dolzan V
Thromb Haemost; 2006 May; 95(5):782-7. PubMed ID: 16676068
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.
Liang R; Li L; Li C; Gao Y; Liu W; Hu D; Sun Y
J Thromb Thrombolysis; 2012 Jul; 34(1):120-5. PubMed ID: 22528326
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
[TBL] [Abstract][Full Text] [Related]
16. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
[TBL] [Abstract][Full Text] [Related]
17. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.
El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM
Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing warfarin dose requirements in African-Americans.
Momary KM; Shapiro NL; Viana MA; Nutescu EA; Helgason CM; Cavallari LH
Pharmacogenomics; 2007 Nov; 8(11):1535-44. PubMed ID: 18034618
[TBL] [Abstract][Full Text] [Related]
19. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients.
Ohno M; Yamamoto A; Ono A; Miura G; Funamoto M; Takemoto Y; Otsu K; Kouno Y; Tanabe T; Masunaga Y; Nonen S; Fujio Y; Azuma J
Eur J Clin Pharmacol; 2009 Nov; 65(11):1097-103. PubMed ID: 19582440
[TBL] [Abstract][Full Text] [Related]
20. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
Ghozlan MF; Foad DA; Darwish YW; Saad AA
Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
